FORM 51-102F3

Material Change Report

1. **Name and Address of Company**
   Hemostemix Inc. (the "**Issuer**")
   Bay 1, 5220 Duncan Avenue
   PO Box 10
   Blackfalds, Alberta T0M 0J0

2. **Date of Material Change**
   September 26, 2017

3. **News Release**
   A news release setting out information relating to the material change described herein was distributed by the Issuer on September 26, 2017, and was disseminated through the facilities of Marketwired and filed on SEDAR. A copy of the news release is attached as Schedule "A".

4. **Summary of Material Change**
   The Issuer has announced agreement with CRO Service Provider, Topstone Research Inc.

5. **Full Description of Material Change**
   See the news release attached as Schedule "A".

6. **Reliance on subsection 7.1(2) or (3) of National Instrument 51-102.**
   Not applicable.

7. **Omitted Information**
   No significant facts remain confidential in, an no information has been omitted from, this report.

8. **Executive Officer**
   For further information, please contact Kyle Makofka, Chief Restructuring Officer at (403) 506-3373.

9. **Date of Report**
   September 26, 2017

SCHEDULE "A"

News Release

NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

HEMOSTEMIX INC.

Hemostemix Announces Agreement with CRO Service Provider Topstone Research

September 26, 2017, Blackfalds, Alberta - Hemostemix Inc. ("**Hemostemix**" or the "**Company**") (TSX VENTURE: HEM) is pleased to announce it has engaged Topstone Research Inc. ("**Topstone**") to provide clinical research monitoring services, project management, regulatory document management, and related services to advance the Company's international, multicenter, Phase II clinical trial for patients with critical limb ischemia (CLI). Topstone, is a Toronto, Ontario based global full-service contract research organization ("**CRO**") service provider.

Spanning across multiple therapeutic areas of experience, Topstone develops inventive approaches designed to continually improve clinical research and meet the specific study needs of its clients. Putting the patient at the forefront, Topstone takes a patient-centered approach to recruitment and conduct of clinical trials and has developed efficient ways to identify, target, recruit and retain participants.

Beginning with its engagement of Drive Capital, management of the Company has been actively reviewing and evaluating proposals from various CROs with the goal of being prepared to re-start the Company's CLI trial. With the engagement of Topstone, the Company now expects to be able to do so in an effective and efficient manner.

The CLI trial will continue to be a randomized, placebo-controlled, double blind phase 2 clinical trial to confirm the safety and efficacy of the Company's lead product, ACP-01, a proprietary stem-cell therapy derived from a patient's own blood.

Under the current approved protocols of the Food and Drug Administration of the United States Department of Health and Human Services (the "**FDA**") and Health Canada, the study is designed to assess the efficacy of ACP-01, particularly with respect to the study's placebo arm. It is anticipated that an interim analysis will reinforce the safety record of the therapy, as shown in previous Phase I trials, and provide a clear view of the effectiveness of the therapy. In advance of completing the Phase II trial, the ACP-01 therapy may be made available through partnerships via the "right-to-try" law enacted recently in Texas, USA.

In the USA and Europe combined, it is estimated that 5-6 million people suffer from critical limb ischemia (CLI) associated with peripheral artery diseases (PAD). CLI is the most severe and deadliest form of PAD. In 2015, almost 20 million citizens of the United States suffered from PAD. CLI is characterized by narrowing and hardening of the arteries in the patient's limb(s) caused and/or aggravated by diabetes, Buerger's Disease, other diseases and smoking. With decreased blood flow to the affected extremity, patients can suffer a host of complications including nerve and tissue damage. In advanced stages, limb ischemia can lead to gangrene, which often requires treatment with amputation. The disease is associated with a high rate of mortality and the need for frequent hospitalization from surgical complications.

Kyle Makofka, Chief Restructuring Officer commented, "We are very excited about being in a position to work with Topstone and to re-start the Company's CLI trial. We considered a wide range of potential partners for this project and Topstone demonstrated the capability not only to ensure the highest standards of quality, but also an ongoing commitment to ensure the most efficient methods are consistently used and to understand our product, needs and timelines. CLI is a debilitating disease which frequently results in loss of limbs and lives. Our therapy aims to save patients from amputation and provide a better quality of life."

ABOUT HEMOSTEMIX INC.

Hemostemix is a public clinical-stage biotechnology company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments. It is the first clinical-stage biotech company to test a stem-cell therapy in an international, multicenter, Phase II clinical trial for patients with critical limb ischemia (CLI), a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs. The Phase II trial targets a participant's diseased tissue with proprietary cells grown from his or her blood that can support the formation of new blood vessels.

Hemostemix Inc. is traded on the TSX Venture Exchange under the trading symbol HEM. To find out more visit hemostemix.com or email office@hemostemix.com.

Contact:

Kyle Makofka,
Chief Restructuring Officer
Bay 1, 5220 Duncan Avenue,
PO Box 10
Blackfalds, Alberta T0M 0J0
Phone: (403) 506-3373
E-Mail: kmakofka@drivecapital.ca

Forward-Looking Statements

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," and similar expressions, or that events or conditions "will," "would," "may," "could," or "should" occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management on the date such statements were made. By their nature forward-looking statements are subject to known and unknown risks, uncertainties, and other factors which may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company's stage of development, long-term capital requirements and future ability to fund operations, future developments in the Company's markets and the markets in which it expects to compete, risks associated with its strategic alliances and the impact of entering new markets on the

Company's operations. Each factor should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.